NEW YORK (GenomeWeb News) — Morphosys today said it has expanded a 2-year-old marketing agreement with GeneFrontier to include HuCAL-based research, and the sales of any resulting antibody products.
 
The original agreement, signed in 2004, gave Tokyo-based GeneFrontier rights to market the Human Combinatorial Antibody Library technology in Japan for research and therapeutic applications.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.